ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF

(19)

(11)

EP 3 480 215 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	28.07.2021 Bulletin 2021/30

(45)	Mention of the grant of the patent:
	23.06.2021 Bulletin 2021/25

(21)	Application number: 18204950.2

(22)	Date of filing: 18.11.2014

(51)

International Patent Classification (IPC):

C07K 16/28^(2006.01)
A61K 39/395^(2006.01)
C07K 16/32^(2006.01)

C12N 15/63^(2006.01)
A61P 35/00^(2006.01)
A61K 47/68^(2017.01)

(54)	ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF ANTIKÖRPER GEGEN HER2 UND KONJUGAT DARAUS ANTICORPS ANTI-HER2 ET SON CONJUGUÉ

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

19.11.2013 CN 201310586326

(43)	Date of publication of application:
	08.05.2019 Bulletin 2019/19

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	14864053.5 / 3072907

(73)	Proprietor: RemeGen Co., Ltd.
	Yantai, Shandong 264006 (CN)

(72)	Inventors:
	FANG, Jianmin Yantai, Shandong 264006 (CN) HUANG, Changjiang Yantai, Shandong 264006 (CN) JIANG, Jing Yantai, Shandong 264006 (CN) YAO, Xuejing Yantai, Shandong 264006 (CN) LI, Hongwen Yantai, Shandong 264006 (CN) XU, Qiaoyu Yantai, Shandong 264006 (CN) LI, Zhuanglin Yantai, Shandong 264006 (CN)

(74)	Representative: HGF
	1 City Walk Leeds LS11 9DX Leeds LS11 9DX (GB)

(56)

References cited: :

WO-A1-2011/107957
US-A1- 2011 217 305

WO-A2-2011/147982

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).